BASINGSTOKE, England, June 16 /CNW/ - Effective treatment of anaemia in patients suffering from chronic kidney disease (CKD)(x) is possible with the first erythropoietin product produced in a human cell line.(1)
DYNEPO(R) (epoetin delta), developed using innovative gene activation technology in a human cell line, corrects and maintains haemoglobin levels in patients suffering from anaemia and CKD who are on dialysis, according to the results of a study presented for the first time today at the 11th Congress of the European Hematology Association (EHA).(1)